Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serial FMT Plus Fidaxomicin for Severe/Fulminant CDI
NCT03760484Phase 2Terminated
- Sponsor
- University of Alberta
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fidaxomicin in Clostridioides difficile infection (CDI), sponsored by University of Alberta. Started Jan 2019; status: terminated.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03760484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760484.